Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

L. Taramasso; P. Tatarelli; E. Ricci; G. Madeddu; B. Menzaghi; N. Squillace; G.V. De Socio; C. Martinelli; R. Gulminetti; P. Maggi; G. Orofino; F. Vichi; A. Di Biagio; P. Bonfanti; C. Bellacosa; L. Calza; C. Abeli; B.M. Celesia; C. Grosso; A. Stagno; F. Mazzotta; G. Penco; G. Cassola; L.A. Nicolini; C. Dentone; C. Molteni; L. Palvarini; A. Scalzini; L. Carenzi; G. Rizzardini; L. Valsecchi; L. Cordier; S. Rusconi; V. Colombo; M. Galli; M. Franzetti; A. Sgrelli; E. Mazzotta; G. Parruti; P. Bagella; M.S. Mura; R. Libertone; A. Antinori; S. Di Giambenedetto; M. Guastavigna; P. Caramello

doi:10.1186/s12879-018-3268-5

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

L. Taramasso, P. Tatarelli, E. Ricci, G. Madeddu, B. Menzaghi, N. Squillace, G.V. De Socio, C. Martinelli, R. Gulminetti, P. Maggi, G. Orofino, F. Vichi, A. Di Biagio, P. Bonfanti, C. Bellacosa, L. Calza, C. Abeli, B.M. Celesia, C. Grosso, A. StagnoF. Mazzotta, G. Penco, G. Cassola, L.A. Nicolini, C. Dentone, C. Molteni, L. Palvarini, A. Scalzini, L. Carenzi, G. Rizzardini, L. Valsecchi, L. Cordier, S. Rusconi, V. Colombo, M. Galli, M. Franzetti, A. Sgrelli, E. Mazzotta, G. Parruti, P. Bagella, M.S. Mura, R. Libertone, A. Antinori, S. Di Giambenedetto, M. Guastavigna, P. Caramello

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	357
Journal	BMC Infectious Diseases
Volume	18
Issue number	1
DOIs	https://doi.org/10.1186/s12879-018-3268-5
Publication status	Published - 2018

Keywords

Cholesterol
Dyslipidemia
Framingham risk score
Integrase inhibitors
Rilpivirine
cholesterol
dolutegravir
efavirenz
elvitegravir
high density lipoprotein cholesterol
lipid
low density lipoprotein cholesterol
rilpivirine
ritonavir
triacylglycerol
virus RNA
adult
antiretroviral therapy
Article
cholesterol blood level
cohort analysis
controlled study
drug substitution
drug withdrawal
dyslipidemia
female
follow up
human
Human immunodeficiency virus infection
lipid analysis
major clinical study
male
observational study
prospective study

Access to Document

10.1186/s12879-018-3268-5

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050717684&doi=10.1186%2fs12879-018-3268-5&partnerID=40&md5=e02cb552150d086608625b3c61119e0b

Cite this

Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., De Socio, G. V., Martinelli, C., Gulminetti, R., Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, P., Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., ... Caramello, P. (2018). Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infectious Diseases, 18(1), [357]. https://doi.org/10.1186/s12879-018-3268-5

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). / Taramasso, L.; Tatarelli, P.; Ricci, E.; Madeddu, G.; Menzaghi, B.; Squillace, N.; De Socio, G.V.; Martinelli, C.; Gulminetti, R.; Maggi, P.; Orofino, G.; Vichi, F.; Di Biagio, A.; Bonfanti, P.; Bellacosa, C.; Calza, L.; Abeli, C.; Celesia, B.M.; Grosso, C.; Stagno, A.; Mazzotta, F.; Penco, G.; Cassola, G.; Nicolini, L.A.; Dentone, C.; Molteni, C.; Palvarini, L.; Scalzini, A.; Carenzi, L.; Rizzardini, G.; Valsecchi, L.; Cordier, L.; Rusconi, S.; Colombo, V.; Galli, M.; Franzetti, M.; Sgrelli, A.; Mazzotta, E.; Parruti, G.; Bagella, P.; Mura, M.S.; Libertone, R.; Antinori, A.; Di Giambenedetto, S.; Guastavigna, M.; Caramello, P.

In: BMC Infectious Diseases, Vol. 18, No. 1, 357, 2018.

Research output: Contribution to journal › Article › peer-review

Taramasso, L, Tatarelli, P, Ricci, E, Madeddu, G, Menzaghi, B, Squillace, N, De Socio, GV, Martinelli, C, Gulminetti, R, Maggi, P, Orofino, G, Vichi, F, Di Biagio, A, Bonfanti, P, Bellacosa, C, Calza, L, Abeli, C, Celesia, BM, Grosso, C, Stagno, A, Mazzotta, F, Penco, G, Cassola, G, Nicolini, LA, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Rusconi, S, Colombo, V, Galli, M, Franzetti, M, Sgrelli, A, Mazzotta, E, Parruti, G, Bagella, P, Mura, MS , Libertone, R , Antinori, A, Di Giambenedetto, S, Guastavigna, M & Caramello, P 2018, 'Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)', BMC Infectious Diseases, vol. 18, no. 1, 357. https://doi.org/10.1186/s12879-018-3268-5

Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infectious Diseases. 2018;18(1). 357. https://doi.org/10.1186/s12879-018-3268-5

Taramasso, L. ; Tatarelli, P. ; Ricci, E. ; Madeddu, G. ; Menzaghi, B. ; Squillace, N. ; De Socio, G.V. ; Martinelli, C. ; Gulminetti, R. ; Maggi, P. ; Orofino, G. ; Vichi, F. ; Di Biagio, A. ; Bonfanti, P. ; Bellacosa, C. ; Calza, L. ; Abeli, C. ; Celesia, B.M. ; Grosso, C. ; Stagno, A. ; Mazzotta, F. ; Penco, G. ; Cassola, G. ; Nicolini, L.A. ; Dentone, C. ; Molteni, C. ; Palvarini, L. ; Scalzini, A. ; Carenzi, L. ; Rizzardini, G. ; Valsecchi, L. ; Cordier, L. ; Rusconi, S. ; Colombo, V. ; Galli, M. ; Franzetti, M. ; Sgrelli, A. ; Mazzotta, E. ; Parruti, G. ; Bagella, P. ; Mura, M.S. ; Libertone, R. ; Antinori, A. ; Di Giambenedetto, S. ; Guastavigna, M. ; Caramello, P. / Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). In: BMC Infectious Diseases. 2018 ; Vol. 18, No. 1.

@article{ba68b6bd69c146c186f85d7095377731,

title = "Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)",

keywords = "Cholesterol, Dyslipidemia, Framingham risk score, Integrase inhibitors, Rilpivirine, cholesterol, dolutegravir, efavirenz, elvitegravir, high density lipoprotein cholesterol, lipid, low density lipoprotein cholesterol, rilpivirine, ritonavir, triacylglycerol, virus RNA, adult, antiretroviral therapy, Article, cholesterol blood level, cohort analysis, controlled study, drug substitution, drug withdrawal, dyslipidemia, female, follow up, human, Human immunodeficiency virus infection, lipid analysis, major clinical study, male, observational study, prospective study",

author = "L. Taramasso and P. Tatarelli and E. Ricci and G. Madeddu and B. Menzaghi and N. Squillace and {De Socio}, G.V. and C. Martinelli and R. Gulminetti and P. Maggi and G. Orofino and F. Vichi and {Di Biagio}, A. and P. Bonfanti and C. Bellacosa and L. Calza and C. Abeli and B.M. Celesia and C. Grosso and A. Stagno and F. Mazzotta and G. Penco and G. Cassola and L.A. Nicolini and C. Dentone and C. Molteni and L. Palvarini and A. Scalzini and L. Carenzi and G. Rizzardini and L. Valsecchi and L. Cordier and S. Rusconi and V. Colombo and M. Galli and M. Franzetti and A. Sgrelli and E. Mazzotta and G. Parruti and P. Bagella and M.S. Mura and R. Libertone and A. Antinori and {Di Giambenedetto}, S. and M. Guastavigna and P. Caramello",

note = "Export Date: 18 January 2019 CODEN: BIDMB Correspondence Address: Taramasso, L.; University of Genoa, Department of Health Sciences (DISSAL)Italy; email: taramasso.lucia@gmail.com",

year = "2018",

doi = "10.1186/s12879-018-3268-5",

language = "English",

volume = "18",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

AU - Taramasso, L.

AU - Tatarelli, P.

AU - Ricci, E.

AU - Madeddu, G.

AU - Menzaghi, B.

AU - Squillace, N.

AU - De Socio, G.V.

AU - Martinelli, C.

AU - Gulminetti, R.

AU - Maggi, P.

AU - Orofino, G.

AU - Vichi, F.

AU - Di Biagio, A.

AU - Bonfanti, P.

AU - Bellacosa, C.

AU - Calza, L.

AU - Abeli, C.

AU - Celesia, B.M.

AU - Grosso, C.

AU - Stagno, A.

AU - Mazzotta, F.

AU - Penco, G.

AU - Cassola, G.

AU - Nicolini, L.A.

AU - Dentone, C.

AU - Molteni, C.

AU - Palvarini, L.

AU - Scalzini, A.

AU - Carenzi, L.

AU - Rizzardini, G.

AU - Valsecchi, L.

AU - Cordier, L.

AU - Rusconi, S.

AU - Colombo, V.

AU - Galli, M.

AU - Franzetti, M.

AU - Sgrelli, A.

AU - Mazzotta, E.

AU - Parruti, G.

AU - Bagella, P.

AU - Mura, M.S.

AU - Libertone, R.

AU - Antinori, A.

AU - Di Giambenedetto, S.

AU - Guastavigna, M.

AU - Caramello, P.

N1 - Export Date: 18 January 2019 CODEN: BIDMB Correspondence Address: Taramasso, L.; University of Genoa, Department of Health Sciences (DISSAL)Italy; email: taramasso.lucia@gmail.com

PY - 2018

Y1 - 2018

KW - Cholesterol

KW - Dyslipidemia

KW - Framingham risk score

KW - Integrase inhibitors

KW - Rilpivirine

KW - cholesterol

KW - dolutegravir

KW - efavirenz

KW - elvitegravir

KW - high density lipoprotein cholesterol

KW - lipid

KW - low density lipoprotein cholesterol

KW - rilpivirine

KW - ritonavir

KW - triacylglycerol

KW - virus RNA

KW - adult

KW - antiretroviral therapy

KW - Article

KW - cholesterol blood level

KW - cohort analysis

KW - controlled study

KW - drug substitution

KW - drug withdrawal

KW - dyslipidemia

KW - female

KW - follow up

KW - human

KW - Human immunodeficiency virus infection

KW - lipid analysis

KW - major clinical study

KW - male

KW - observational study

KW - prospective study

U2 - 10.1186/s12879-018-3268-5

DO - 10.1186/s12879-018-3268-5

M3 - Article

VL - 18

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 357

ER -